Abstract | The resurgence of research into cancer metabolism has recently broadened interests beyond glucose and the Warburg effect to other nutrients, including glutamine. Because oncogenic alterations of metabolism render cancer cells addicted to nutrients, pathways involved in glycolysis or glutaminolysis could be exploited for therapeutic purposes. In this Review, we provide an updated overview of glutamine metabolism and its involvement in tumorigenesis in vitro and in vivo, and explore the recent potential applications of basic science discoveries in the clinical setting.
Glucose has been central to the study of cancer metabolism following Otto Warburg's pioneering work on aerobic glycolysis 1 , whereas studies of other nutrients, such as glutamine, have been at the margins of the cancer metabolism literature until recently. Hans Krebs, famed for characterization of the tricarboxylic acid (TCA) cycle, studied glutamine metabolism in animals in 1935 and documented its importance in organismal homeo stasis. Subsequently, the role of glutamine in cell growth and cancer cell biology has slowly been appreciated (FIG. 1) and has been a subject of several comprehensive reviews 2, 3 . Given the many energy-generating and biosynthetic roles that glutamine plays in growing cells, which are discussed and updated in this Review, inhibition of glutaminolysis has the potential to effectively target cancer cells.
There are nine amino acids (isoleucine, leucine, methionine, valine, phenylalanine, tyrosine, histidine, threonine and lysine) that humans cannot synthesize and hence are considered essential amino acids. Five amino acids (alanine, aspartate, asparagine, glutamate and serine) are believed to be dispensable, because they can be readily synthesized. Glutamine belongs to a group of amino acids that are conditionally essential, particularly under catabolic stressed conditions such as the postoperative period, injury or sepsis, in which glutamine consumption by the kidney, gastrointestinal tract and immune compartment rises dramatically 4 . Cells of the intestinal mucosa are particularly dependent on glutamine, and they rapidly undergo necrosis after glutamine depletion 4 . These observations mirror the dependence of growing cancer cells on glutamine 5 , with some cancer cells dying rapidly if they are deprived of glutamine 6 . Circulating glutamine is the most abundant amino acid (~500 μM) 7 , making up more than 20% of the free amino acid pool in blood and 40% in muscle 8 . Although diet can serve as a source of glutamine from digested foods absorbed through the small intestine, the endothelium of which retains up to 30% of dietary glutamine, glutamine can be considered a non-essential amino acid at the organismal level owing to the fact that the muscle and other organs synthesize glutamine as a scavenger for ammonia produced by the metabolism of other amino acids 9 . In fact, glutamine is held at a fairly constant level in the circulation, presumably owing to de novo synthesis and release from the skeletal muscle, lung and adipose tissue 3, 10, 11 . The kidney releases ammonia from glutamine to maintain acid-base homeostasis 12 , and the liver and kidney eliminate excess nitrogen in the form of urea from glutamine via the urea cycle, another process first identified by Krebs 13 . In rapidly dividing cells such as lymphocytes, enterocytes of the small intestine and especially cancer cells, glutamine is avidly consumed and used for both energy generation and as a source of carbon and nitrogen for biomass accumulation 14 .
Glutamine metabolism
The maintenance of high levels of glutamine in the blood provides a ready source of carbon and nitrogen to support biosynthesis, energetics and cellular homeo stasis that cancer cells may exploit to drive tumour growth. Glutamine is transported into cells through one of many transporters 15 , such as the heavily studied SLC1A5 (also known as ASCT2; FIG. 2) 16 , and can then be used for biosynthesis or exported back out of the cell by antiporters in exchange for other amino acids such as leucine, through the L-type amino acid transporter 1 (LAT1, a heterodimer of SLC7A5 and SLC3A2) antiporter 17 . Glutaminederived glutamate can also be exchanged through the xCT (a heterodimer of SLC7A11 and SLC3A2; FIG. 3) anti porter for cystine, which is quickly reduced to cysteine inside the cell 18 . 1 
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Macropinocytosis
A type of endocytosis in which extracellular fluid and nutrients are engulfed and taken up into vesicles called macropinosomes. The contents can then be digested by lysosomal degradation to provide nutrients for metabolism.
Autophagy
Refers to macroautophagy, which is a process of bulk cytoplasmic and organelle degradation by specialized organelles called autophagosomes, which then deliver the contents to the lysosome. Autophagy is increased under many forms of stress and can provide nutrients for metabolism.
Aminotransferases
A class of enzymes, also known as transaminases, that catalyse the reaction between an α-keto acid such as pyruvate and an α-amino acid to form a different amino acid and α-keto acid. For example, glutamatepyruvate transaminase (GPT, also known as alanine aminotransferase) transfers a nitrogen from glutamate to pyruvate to make alanine and α-ketoglutarate.
Oncogenotypes
The genetic or epigenetic alterations (to activate an oncoprotein or disable a tumour suppressor pathway) that drive the evolution and phenotype of a given tumour.
In addition to transport, cancer cells can acquire glutamine through the breakdown of macromolecules under nutrient-deprived conditions. Macropinocytosis, which can have a role in normal biology and is active in most non-cancerous cells 19 , can be stimulated by oncogenic RAS 20 , enabling cancer cells to scavenge extracellular proteins, which are then degraded to amino acids, including glutamine, supplying metabolites for survival 21, 22 . This process must be tightly controlled 23 , as excess RAS can hyperactivate macropinocytosis, leading to cell death, in a process previously mis identified as autophagic cell death 24 . The complex relationship between glutamine metabolism and autophagy is discussed below, but it is notable that some RAS-transformed cancer cells derive glutamine and maintain metabolic flux from autophagic degradation of intracellular proteins 25, 26 . Energy generation. Upon entry into the cell via transporters, glutamine is converted by mitochondrial glutaminases to an ammonium ion and glutamate, which is further catabolized through two different pathways (FIG. 2) . Interestingly, despite its importance, the mitochondrial glutamine transporter has not yet been definitively identified and characterized 27 . Glutaminase, which, as Krebs determined, exists in multiple tissuespecific versions, is encoded by two genes in mammals, kidney-type glutaminase (GLS) and liver-type glutaminase (GLS2) 28, 29 . Glutamate can then be converted to α-ketoglutarate, which enters the TCA cycle to generate ATP through production of NADH and FADH 2 . As Lehninger first described 30 , glutamate can be converted to α-ketoglutarate by either glutamate dehydrogenase (encoded by the highly conserved and more broadly expressed GLUD1 or the hominoid-specific GLUD2, henceforth collectively termed GLUD), which is an ammonia-releasing process, or by several nonammonia-producing aminotransferases, which transfer nitrogen from glutamate to produce another amino acid and α-ketoglutarate 30 . Proliferating cells including cancer cells and activated lymphocytes use glutamine as an energy-generating substrate [31] [32] [33] . In some tumour cells, a portion of metabolized glutamine is converted to pyruvate through the malic enzymes 31,34 , but as discussed below, this is probably not an energy-generating process. Notably, and as will be expanded on below, proliferating cells incorporate most of the glutamine they use for biomass for building protein and nucleotides
.
Glutamine enzymes in cancer. The expression of enzymes involved in glutamine metabolism varies widely in cancers and is affected by tissue of origin and oncogenotypes, which rewire glutamine metabolism for energy generation and stress suppression. Of the two glutaminase enzymes 28 , GLS is more broadly expressed in normal tissue and is thought to have a crucial role in many cancers, whereas GLS2 expression is restricted primarily to the liver, brain, pituitary gland and pancreas 36 . Alternative splicing adds further complexity, as GLS pre-mRNA is spliced into either glutaminase C (GAC) or kidney-type glutaminase (KGA) isoforms [37] [38] [39] . The two GLS isoforms and GLS2 also differ in their regulation and activity. GLS but not GLS2 is inhibited by its product glutamate, whereas GLS2 but not GLS is activated by its product ammonia in vitro 28, 29 . Although both GLS and GLS2 are activated by inorganic phosphate, GLS (and particularly GAC) shows a much larger increase in catalysis in the presence of inorganic phosphate 37 . Sirtuin 5 (SIRT5), which can be overexpressed in lung cancer 40 , can desuccinylate GLS to suppress its enzymatic activity 41 , whereas SIRT3 can deacetylate GLS2 to promote its increased activity with caloric restriction 42 . The availability of phosphate, acetyl-CoA and succinyl-CoA is affected by nutrient uptake and metabolism, suggesting that GLS and GLS2 activity may be responsive to the metabolic state of the cell. Additionally, GLS is regulated through transcription 43 , RNA-binding protein regulation of alternative splicing [44] [45] [46] [47] , post-transcriptional regulation by microRNAs (mi RNAs) and pH stabilization of the GLS mRNA 48, 49 , and protein degradation via the anaphase-promoting complex (APC)-CDH1 (also known as FZR1) E3 ubiquitin ligase complex 50, 51 . Expression of GAC, which is more active than KGA, is increased in several cancer types, suggesting that GLS alternative splicing may have an important role in the presumed higher glutaminolytic flux in cancer 18, 37, 45, 47, [52] [53] [54] . By contrast, the role of GLS2 in cancer seems more complex. Silenced by promoter methylation in liver cancer, colorectal cancer and glioblastoma, re-expression of GLS2 has been shown to have tumour suppressor activities in colony formation assays [55] [56] [57] [58] [59] . In fact, a recent study 60 showed that GLS2, in a nonmetabolic function, sequesters the small GTPase RAC1 to suppress metastasis. However, GLS2 seems to support growth and promote ionizing radiation resistance in some types of cancer 61 . Indeed, GLS2 is induced by the tumour suppressor p53 and related proteins p63 and p73 (REFS 55, 56, 62, 63) , suggesting that perhaps it functions in resistance to ionizing radiation, or is important in cancers that still possess wild-type p53. Additionally, GLS2 is a crucial downstream target of the NMYC oncoprotein in neuroblastoma 64, 65 . The context-dependent role of GLS2 in cancer clearly merits further study.
Once produced via glutaminase, glutamate is further converted to α-ketoglutarate through one of two mechanisms 30 (FIG. 2) . GLUD catalyses the reversible deamination of glutamate to produce α-ketoglutarate and release ammonium. This reaction is at near-thermodynamic equilibrium in the liver, and so GLUD operates in both directions in this organ 66 , but in cancer it is thought to operate chiefly in the direction of α-ketoglutarate 67 , and so GLUD activity will be discussed in this context for the purpose of this Review. Like GLS, GLUD is controlled through post-translational modifications and allosteric regulation. It is activated by ADP and inactivated by GTP, palmitoyl-CoA and SIRT4-dependent ADP ribosylation [68] [69] [70] [71] . Interestingly, GLUD is also allosterically activated by leucine, and mTOR (which itself is activated by leucine availability 17, 72 ) can promote GLUD activity by suppressing SIRT4 expression 73, 74 . These observations suggest that a low energetic state might induce GLUD allosterically via ADP to increase ATP production, and high leucine availability could also induce GLUD allosterically and through mTOR-mediated suppression of SIRT4.
Aminotransferases are enzymes that convert glutamate to α-ketoglutarate without producing ammonia (FIG. 3) . Two of these enzymes, alanine aminotransferase and aspartate aminotransferase, are well known in clinical medicine as 'liver enzymes' or markers of liver pathology 75, 76 . Glutamate-pyruvate transaminase (GPT, also known as alanine aminotransferase) transfers nitrogen from glutamate to pyruvate to make alanine and α-keto glutarate, and is encoded in humans by GPT (cytoplasmic isoform) and GPT2 (mitochondrial isoform). Glutamate-oxaloacetate transaminase (GOT, also known as aspartate aminotransferase), which transfers nitrogen from glutamate to oxaloacetate to produce aspartate and α-ketoglutarate, is encoded in humans by GOT1 (cytoplasmic isoform) and GOT2 (mitochondrial isoform). Phosphoserine aminotransferase 1 (PSAT1), as part of the serine biosynthesis pathway, transfers nitrogen from glutamate to 3-phosphohydroxypyruvate to make phosphoserine and α-ketoglutarate. Different aminotransferases show different tissue distribution: aspartate aminotransferase activity is high across most tissues, whereas alanine aminotransferase activity is highest in the liver, although expression is still fairly universal 36, 77, 78 . However, amino transferases such as PSAT1 may be inappropriately expressed in tumours 79 . The potential importance of which enzyme converts glutamate to α-keto glutarate in cancer cell physiology is discussed below.
Glutamine and ATP: what else?
Amino acid production. The nitrogen from glutamine supports the levels of many amino acid pools in the cell through the action of aminotransferases 35 (FIG. 3) . , or is converted to glutamate by glutaminase (GLS or GLS2)
28
. Glutamate can contribute to the synthesis of glutathione 110 and has many other metabolic fates in the cell that have an impact on several inborn errors of metabolism, which were recently reviewed
211
. Glutamate is converted to α-ketoglutarate (α-KG) through one of two sets of enzymes, glutamate dehydrogenase (GLUD1 or GLUD2, henceforth referred to collectively as GLUD) or aminotransferases 30 . Whereas the by-product of GLUD is NH 4 + , the by-product of aminotransferase reactions is other amino acids. Note that aminotransferases may be present in either the cytoplasm or the mitochondria. α-KG enters the tricarboxylic acid (TCA) cycle and can provide energy for the cell. Malate exiting the TCA cycle can produce pyruvate and NADPH for reducing equivalents 31 , and oxaloacetate (OAA) can be converted into aspartate to support nucleotide synthesis 
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One-carbon metabolism pathway
A pathway centred on the metabolism of folate, an important carbon donor for DNA methylation and purine nucleotide synthesis. This pathway is linked to the de novo biosynthesis pathways of serine and glycine.
Reductive carboxylation
A process that occurs in some normal and cancer cells whereby α-ketoglutarate proceeds 'backwards' through the tricarboxylic acid cycle, being reduced through the consumption of NADPH by isocitrate dehydrogenase in the non-canonical reverse reaction to form citrate. This citrate may then be used in fatty acid synthesis.
Integrated stress response (ISR).
A stress response pathway that responds to various cellular insults, including amino acid deprivation, through the GCN2 kinase, to phosphorylate eukaryotic translation initiation factor 2α (eIF2α), halt general cap-dependent protein translation and increase transcription of endoplasmic reticulum chaperone proteins. The ISR may eventually result in apoptotic cell death if the stress is not resolved.
Separate from transamination reactions, carbon and nitrogen from glutamate can be used to produce proline, which has a key role in the production of the extracellular matrix protein collagen 80 (FIG. 3) . Although proline can be degraded to glutamate 81 , the MYC oncoprotein can alter the expression of proline synthesis and degradation enzymes to promote the net synthesis of proline from glutamine-derived glutamate 82 . Overall, tracer experiments determined that at least 50% of non-essential amino acids used in protein synthesis by cancer cells in vitro can be directly derived from glutamine 16, 83 . Although various glutamine-derived amino acids contribute to cancer cell survival, recent studies have shown that aspartate biosynthesis, which can depend on both glutamine flux through the TCA cycle and glutamate transamination 84, 85 , is especially crucial owing to its key role in both purine and pyrimidine biosynthesis to support cell division [84] [85] [86] , as discussed in greater detail below.
Reductive carboxylation and fatty acid synthesis.
Cancer cells take up large amounts of glucose, but most of this carbon is excreted as lactate rather than being metabolized in the TCA cycle 7 , potentially depriving the cells of the citrate derived from the TCA cycle that supports fatty acid synthesis (FIG. 2) . Glutamine metabolism can serve as an alternative source of carbon to the TCA cycle to fuel fatty acid synthesis, through reductive carboxylation, which is a process by which glutaminederived α-ketoglutarate is reduced through the consumption of NADPH by isocitrate dehydro genases (IDHs) in the non-canonical reverse reaction, to form citrate 87 . Reductive carboxylation, the importance of which is still somewhat controversial 88 , seems to be a major source of carbon for lipid synthesis in cancer cells that are hypoxic, have constitutive hypoxia-inducible factor-α (HIFα) stabilization or have mitochondrial defects [89] [90] [91] [92] . Although the contribution of reductive carboxylation to lipid formation from glutamine remains unclear owing to the possibility of isotope exchange 88 , studies suggest that reductive carboxylation occurs in vivo and can support lipogenesis for tumour growth and progression 89, 93, 94 and can also control the levels of mitochondrial reactive oxygen species (ROS) 95 .
Protein synthesis, trafficking and stress pathway suppression. Several of the metabolic fates of glutamine directly support protein synthesis and trafficking, and suppress stress responses carried out by two related pathways -the integrated stress response (ISR) and Glutamate acts as a nitrogen donor for the transamination involved in the production of 'dispensable amino acids' -alanine, aspartate and serine -through the actions of glutamate-oxaloacetate transaminase (GOT), glutamate-pyruvate transaminase (GPT) and phosphoserine aminotransferase 1 (PSAT1), respectively. Glutamine can also act as a nitrogen donor for asparagine through asparagine synthetase (ASNS). In a reaction independent of transamination, proline can be synthesized by conversion of glutamate to pyrroline-5-carboxylate (P5C) by pyrroline-5-carboxylate synthase (P5CS; also known as ALDH18A1) and subsequently to proline by pyrroline-5-carboxylate reductase 1 (PYCR1) and PYCR2. Glutamine also contributes to the tripeptide glutathione (composed of glutamate, cysteine and glycine), which neutralizes the reactive oxygen species (ROS), including H 2 O 2 (REF. 110 ). The first step in glutathione synthesis is the condensation of glutamate and cysteine through glutamate-cysteine ligase (GCL; not shown in the figure). Glutamine input contributes directly to the availability of cysteine and glycine for production of glutathione. Glutamate can be exchanged for cystine (which is quickly reduced to cysteine inside the cell) through the xCT antiporter (a heterodimer of SLC7A11 and SCL3A2), which has been shown to be important in various cancers and has been considered as a drug target 18, 212 . Glycine is next added by glutathione synthetase (GSS; not shown in the figure). Additionally, glutamate can contribute to glycine through transamination by PSAT1 into phosphoserine (pSer) and α-ketoglutarate (α-KG) and subsequent conversion to glycine through serine hydroxymethyltransferase (SHMT; not shown in the figure) as part of the one-carbon metabolism pathway, which has been shown in numerous studies to be crucial in cancer metabolism and is also reviewed in this Focus issue by Vousden 139, 140, 213 . GLS, kidney-type glutaminase; GLS2, liver-type glutaminase; GLUD, glutamate dehydrogenase; OAA, oxaloacetate. 
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Endoplasmic reticulum (ER) stress
Refers to various stresses that lead to protein misfolding and activate the unfolded protein response (UPR). The UPR, which shares molecular machinery with the integrated stress response, halts cap-dependent translation, induces expression of ER chaperone proteins and can lead to death if the stress is not resolved.
Cap-dependent translation
In most eukaryotic mRNAs, translation relies on eukaryotic translation initiation factor 4E (eIF4E) binding to the 5′ mRNA cap (a modified nucleotide), along with the ribosome and other initiation factors. Certain stress pathways including endoplasmic reticulum stress and the integrated stress response inhibit cap-dependent translation through inhibitory phosphorylation of the initiation factor eIF2α.
the endoplasmic reticulum (ER) stress pathway (FIG. 4) . Glutamine input thus supports the overall amino acid pools of the cell to suppress the ISR, which is otherwise activated under amino acid deprivation by the amino acid-sensing kinase GCN2 (encoded by EIF2AK4) (FIG. 3) . Phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) by GCN2 inhibits general cap-dependent translation via the ISR but induces cap-independent synthesis of the activating transcription factor 4 (ATF4), which in turn induces a pathway to increase transcription of ER-associated chaperones, halt cap-dependent translation and eventually result in cell death 96 . Glutamine deprivation can lead directly to uncharged tRNAs, or to a depletion of downstream products such as asparagine, which leads indirectly to uncharged tRNAs, all of which can activate GCN2 and induce ATF4 translation. Suppression of the ISR by glutamine input has been shown to be crucial for the survival of several cancer cell and tumour types, including neuroblastoma and breast cancer 65, 97, 98 . It was also observed that GCN2 is activated in mice in response to treatment with asparaginase 99 , which is approved by the US Food and Drug Administration (FDA) for the treatment of acute lymphoblastic leukaemia (ALL) and may deplete serum asparagine and glutamine [100] [101] [102] .
Glutamine also contributes to the synthesis of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) as part of the hexosamine biosynthesis pathway, which is required for glycosylation, proper ER-Golgi trafficking and suppression of the ER stress pathway, also upstream of ATF4 induction (FIG. 4) . Aberrant expression and activity of O-linked β-N-acetylglucosamine transferase (OGT), which links UDP-GlcNAc to proteins, was shown to be crucial for the survival and progression of breast cancer, prostate cancer and chronic lymphocytic leukaemia [103] [104] [105] . Thus, glutamine input directly maintains translation, protein trafficking and survival through suppression of the ISR and the ER stress pathway 106, 107 . ROS control: glutathione and reducing equivalents. ROSmediated cell signalling can be pro-tumorigenic when at physiological levels 108 , but when levels are in excess, ROS can be highly damaging to macro molecules 109 . ROS are generated from several sources, including the mitochondrial electron transport chain, which can leak electrons to oxygen to generate superoxide (O 2 -). Thus, increased glutamine oxidation can correlate with increased ROS production 108 . However, several glutamine metabolic path ways lead to products that directly control ROS levels; hence, glutamine metabolism is crucial for cellular ROS homeostasis. The best known pathway by which glutamine controls ROS is through synthesis of glutathione. Glutathione is a tri peptide (Glu-Cys-Gly) that serves to neutralize peroxide free radicals. It has long been appreciated that glutamine input is the rate-limiting step for glutathione synthesis 110 , and as shown in FIG. 3 , glutamine is directly and indirectly responsible for the other two amino acid components of glutathione. As glutathione levels are known to correlate with tumorigenesis and drug resistance in cancer 111 , a richer understanding of this pathway may contribute to better cancer treatment strategies. In fact, several studies have shown that acute administration of glutamine to cancer patients receiving radio therapy or chemotherapy reduces treatment toxicity through increased glutathione synthesis 112, 113 . Glutamine also affects ROS homeostasis through production of NADPH via GLUD 114 . Additionally, at least two other related mechanisms provide reducing equivalents for glutathione 31, 34 , by which TCA cycle-derived aspartate or malate is exported to the cytoplasm and then converted to pyruvate to produce NADPH through the malic enzymes. Regulation of mTOR. The TOR pathway senses amino acids and broadly promotes biosynthetic pathways such as protein translation and fatty acid synthesis while inhibiting degradative processes like autophagy 115 . As such, mTOR activity must be tightly controlled to prevent inappropriate cell growth, and glutamine regulates this activity through several mechanisms (FIG. 6) . Amino acid availability stimulates mTOR activity independently of the activating mTOR pathway mutations often found in human cancer 115 , and thus must be maintained regardless of mutation state. Glutamine and other amino acids that support mTOR activity need not come from amino The amino acid-sensing kinase GCN2, a serine-threonine kinase with a regulatory domain that is structurally similar to histidine-tRNA synthetase, is allosterically activated by uncharged tRNAs with amino acid deprivation (including glutamine deprivation) and in turn activates the integrated stress response (ISR) 96, 214, 215 . Glutamine can suppress GCN2 activation through its contribution to amino acid pools by aminotransferases 65, [97] [98] [99] . To control endoplasmic reticulum (ER) homeostasis, glutamine supports protein folding and trafficking through its contribution to uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) as part of the hexosamine biosynthesis pathway. Glutamine is the substrate for glutamine fructose-6-phosphate aminotransferase (GFAT), which is the key rate-limiting enzyme in the hexosamine pathway, and the downstream product UDP-GlcNAc is a substrate for O-linked glycosylation through O-linked β-N-acetylglucosamine transferase (OGT). Thus, glutamine deprivation can lead to improper protein folding and chaperoning and ER stress 210 . A key output of both the ISR and ER stress is activating transcription factor 4 (ATF4), which is induced via cap-independent translation downstream of eukaryotic translation initiation factor 2α (eIF2α) phosphorylation by GCN2 or other kinases 96 . α-KG, α-ketoglutarate; GLS, kidney-type glutaminase; GLS2, liver-type glutaminase. 
Electron transport chain
A series of transmembrane protein complexes, present on the inner membrane of mitochondria, that transfer electrons via redox reactions to the terminal electron acceptor oxygen, which is reduced with binding of protons to a water molecule. This generates a proton gradient that powers ATP synthase to produce ATP. Premature leakage of electrons to oxygen can lead to production of reactive oxygen species.
Glutathione
A tripeptide (glutamatecysteine-glycine) that acts as an important antioxidant. The reduced form (GSH) can react with H 2 O 2 to form the oxidized form (GSSG).
acid transporters, as macropinocytosis-derived amino acids can also support mTOR activation 23 . Conversely, mTOR itself can regulate glutamine metabolism by celltype specific mechanisms, either by inhibiting expression of mitochondrial SIRT4, thereby relieving repression of GLUD 69, 73, 116 , or instead by inhibiting GLUD expression while upregulating expression of aminotransferases 117 , as is discussed further below. The important implication of these findings is that, independently of direct mutations of negative regulators of the mTOR pathway itself, such as tuberous sclerosis 1 (TSC1; also known as hamartin) and TSC2 (also known as tuberin), increased glutamine uptake and metabolism, which is common in many cancers, may also strongly stimulate mTOR activity. The regulation of mTOR by amino acid availability, including that of glutamine, is a rich and evolving field, and more advances will be needed to fully understand this intriguingly intricate process 115 .
Nucleotide biosynthesis. Glutamine directly supports the biosynthetic needs of cell growth and division. Whereas carbon from glutamine is used for amino acid and fatty acid synthesis, nitrogen from glutamine contributes directly to de novo biosynthesis of both purines and pyrimidines 118 . The importance of glutamine as a nitrogen reservoir is underscored by the fact that glutaminedeprived cancer cells undergo cell cycle arrest that cannot be rescued by TCA cycle intermediates such as oxaloacetate but can be rescued by exogenous nucleotides 118, 119 .
In fact, synthesis of nucleotides from exo genous glutamine has been observed in human primary lung cancer samples cultured ex vivo 120 . Glutamine can also contribute to nucleotide biosynthesis through other pathways. Aspartate derived from glutamine via the TCA cycle and transamination (FIGS 2, 3) serves as a crucial source of carbon for purine and pyrimidine synthesis 84, 85 , and provision of aspartate can rescue cell cycle arrest caused by glutamine deprivation 86 . Additionally, glutamine-dependent mTOR signalling may activate the enzyme carbamoylphosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), which catalyses the incorporation of glutamine-derived nitrogen into pyrimidine precursors 118, 121, 122 . It has been suggested that NADPH produced downstream of glutamine metabolism and flux through the malic enzymes can further support nucleo tide synthesis 31 . Overall, glutamine can support bio mass accumulation of fatty acids, amino acids and nucleotides, by directly contributing carbon and nitrogen, indirectly generating reducing equivalents and stimulating the signalling pathways that are necessary for their synthesis.
Autophagy and glutamine. Autophagy and glutamine have a complex relationship that mirrors the complexities of autophagy in cancer initiation and progression. The role of autophagy in cancer seems paradoxical: in some settings, it is tumour suppressive, by limiting the oxidative stress and chromosomal instability that may lead to oncogenic mutations 123, 124 , whereas in other situations, autophagy supports cancer cell survival by providing nutrients and suppressing stress pathways such as p53 (REFS 125, 126) . Thus, autophagy may influence tumour initiation and tumour progression differently, affecting tumour growth in a seemingly contradictory context-dependent manner. Many of the processes affected by glutamine metabolism suppress autophagy. Glutamine suppresses GCN2 activation and the ISR, both of which can otherwise induce autophagy 65, 97, 127 . Glutamine also indirectly stimulates mTOR, which in turn suppresses autophagy through a complex mech anism 17, [128] [129] [130] [131] [132] [133] [134] (recently reviewed by Dunlop and  Tee   135 ). Similarly, ROS can induce autophagy as a stress response 136 but are suppressed by glutamine metabolism through production of glutathione and NADPH 31,34,110 . Conversely, generation of ammonia from glutaminolysis could potentially promote autophagy activation in an autocrine and paracrine manner 137, 138 . Although increased glutamine metabolism in cancer would suppress ROS levels (through glutathione production) as well as ER stress and promote mTOR activity, ammonia release from glutamine metabolism will vary between cancer types. Glutaminase releases ammonia in catalysing the reaction of glutamine to glutamate, and some cancers process glutamate to α-keto glutarate via GLUD (releasing another ammonium ion), whereas others use transamination, which does not release ammonia, as was first described by Lehninger
30
. Similarly, SIRT5 desuccinylates and reduces GLS activity, thus reducing ammonia production and autophagy activation 41 . Through the Figure 5 | Glutamine-derived TCA cycle intermediates can be used via two pathways to produce NADPH and neutralize reactive oxygen species through the malic enzyme. Reduced glutathione (GSH) neutralizes H 2 O 2 with the glutathione peroxidase enzyme, and oxidized glutathione (GSSG) is reduced by NADPH and glutathione reductase to regenerate GSH. In the first pathway, glutamine-derived malate is transported out of the mitochondria, and is converted by malic enzyme 1 (ME1) into pyruvate, reducing one molecule of NADP + to NADPH. In the malate-aspartate shuttle-related second pathway, found in mutant KRAS-transformed cells, aspartate that is produced from glutamate-oxaloacetate transaminase mitochondrial isoform (GOT2)-mediated transamination of glutamine-derived oxaloacetate (OAA) is transported out of the mitochondria. Aspartate is then converted in the cytosol back to OAA by GOT1 and then to malate by malate dehydrogenase 1 (MDH1), which is in turn processed to pyruvate by ME1 to produce one molecule of NADPH
34
. The fate of glutamine-derived pyruvate is similar to that of glucose-derived pyruvate in that much of it is expelled as lactate
31
. α-KG, α-ketoglutarate; TCA, tricarboxylic acid. 
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relative contributions of SIRT5 and GLUD versus transamination, one might speculate that ammonia production downstream of glutamine metabolism could 'tune' autophagy to the specific needs of the tumour cells to maintain organelle turnover, provide nutrients and reduce cell stress.
Divergent paths to α-ketoglutarate
An aspect of glutamine metabolism in cancer that is perhaps under-studied is the consequence of two divergent pathways that convert glutamate to α-ketoglutarate, and the subsequent fate of the nitrogen derived from glutamate (FIG. 7) . The different pathways were first identified more than 30 years ago 30 , and the field has made much progress on the 'how' and 'what' of GLUD versus amino transferase use, but not nearly as much progress on the 'when' or the 'why' . Specifically, the field must still address the relative contributions of each pathway to cancer cell physiology, and how the two different pathways are used depending on tissue of origin, proliferation state, cell health or stress, stage of tumour evolution and oncogenotype.
Reactions via GLUD or aminotransferases result in the production of α-ketoglutarate but have different by-products. In addition to α-ketoglutarate and ammonium, GLUD can produce both NADH and NADPH with different kinetics 114 , which support the TCA cycle, bioenergetics, control of ROS levels and lipid synthesis. In contrast, the by-product of amino transferases is α-ketoglutarate as well as other amino acids such as serine, alanine, aspartate, and asparagine downstream of aspartate, which contribute to several cell functions such as nucleotide biosynthesis, redox control and suppression of the ISR 65, 84, 85, 97, 98, [139] [140] [141] . In breast cancer with genomic amplification of the serine biosynthesis gene phosphoglycerate dehydrogenase (PHGDH), PSAT1 is the major source of glutamine-dependent α-ketoglutarate, through transamination, and breast cancer cells with amplified PHGDH grow poorly after PHGDH depletion compared with those with normal PHGDH levels 142 , underscoring the importance of these reactions in certain tumour types. Alanine is a product of transamination that is highly secreted from some tumour types 30, 141 , which perhaps may safely dispose of nitrogen without ammonia production. Although some tumours are sensitive to the aminotransferase inhibitor aminooxyacetate (AOA) 65, 143 , it is a broad-spectrum inhibitor, and so specific inhibition of individual amino transferases will be required to assess their specific roles in cancer.
The underlying oncogenotype affects these two pathways differentially, which may be related to the metabolic requirements that the oncogenes impose on the cells. MYC upregulates both GLUD and aminotransferases 144 , and seems to require both pathways, depending on the context 67, 145 . In contrast, oncogenic mutant KRAS activity increases aminotransferases and decreases GLUD mRNA expression 34 . The role of mTOR in glutamine metabolism seems highly context and cell-type specific: in mouse embryo fibroblasts (MEFs) and colon and prostate cancer cells, mTOR supports increased activity of GLUD via repression of SIRT4 (REFS 69, 73, 116) , whereas in mouse mammary 3D culture models and human breast cancer, mTOR instead inhibits expression of GLUD while promoting expression of amino transferases, particularly PSAT1 (REF. 117 ). It is notable that mTOR requires constant amino acid input 146 , whereas KRAS drives macropinocytosis 22 , and thus, pathway selection of glutamine catabolism by these two pathways may reflect differing metabolic requirements that we do not yet fully appreciate. Nonetheless, these studies do suggest that transformed cells with strong PI3K-AKT-mTOR, KRAS or MYC pathway activation increase their flux of glutamate to α-ketoglutarate for metabolism and biosynthesis. Some key differences in the two pathways from glutamate to α-ketoglutarate may warrant further studies. Most noticeably, in addition to ammonia release by GLS, GLUD releases an additional ammonium ion and transamination does not. Although ammonia is often thought of as a toxic by-product, cancers can use ammonia to induce autophagy and neutralize intracellular pH 137, 138, 147 , and GLUD can also produce NADPH 114 to reduce glutathione and lead to lower levels of ROS 114 . Together, these pathways could reduce cell stress and promote survival in some cancers 148 . GLUD catalyses a reaction that is reversible; however, the high K m for ammonia limits this reaction to deamination of glutamate in most tissues, with the exception of the liver 66, 149 . In contrast, Figure 6 | Glutamine controls mTOR activity. Amino acids stimulate the mTOR pathway, and amino acid pools rely on glutamine to be maintained. Specifically, arginine and leucine are two amino acids that can together almost fully stimulate mTOR complex 1 (mTORC1) through activation of the RAS-related GTPase (RAG) complex, which in turn recruits mTORC1 to the lysosome and stimulates its activity 72, 133, 216 . Glutamine can contribute to mTORC1 activation by being exchanged for essential amino acids, including leucine, through the large neutral amino acid transporter 1 (LAT1; a heterodimer of SLC7A5 and SLC3A2) antiporter 17 . This RAG-dependent regulation of mTOR is probably dependent on the lysosomal amino acid transporter SLC38A9, which transports glutamine, arginine and leucine as substrates 129, 132, 133 , as well as the leucine sensor sestrin 2 (not shown in the figure) 217, 218 . Although the mechanism is not well understood, α-ketoglutarate (α-KG) may regulate RAGB activity and mTOR activation downstream of glutamine metabolism 219 . Several RAG-independent pathways of mTOR regulation by glutamine have also been identified. Glutamine promotes mTOR localization to the lysosome (and thus activity) through the RAS family member ADP ribosylation factor 1 (ARF1) in a poorly understood mechanism, as well as the TTT-RUVBL1/2 complex (not shown in the figure) 128, 130 . GLS, kidney-type glutaminase; GLS2, liver-type glutaminase; GLUD, glutamate dehydrogenase. 
GLS or GLS2
2-Hydroxyglutarate (2HG). An α-hydroxy acid sometimes produced at high levels by cancer cells, which structurally resembles α-ketoglutarate and so inhibits α-ketoglutarate-dependent enzymes such as the Jumonji-family histone demethylases. The d-2HG enantiomer is produced downstream of mutant isocitrate dehydrogenase enzymes in glioma and acute myelogenous leukaemia, and the l-2HG enantiomer is produced under hypoxia.
aminotransferases are freely reversible, and thus may provide more metabolic plasticity to certain cancer cells that rely on them. Furthermore, GLUD results in disposal of a nitrogen atom in ammonium, whereas amino transferase supports a much more biosynthetic phenotype that may better support rapidly growing cancer cells. In fact, a recent study 32 suggests that rapidly dividing mammary epithelial cells in culture as well as highly proliferative human breast cancers upregulate aminotransferases and downregulate GLUD expression. The authors show that growing cells incorporate the nitrogen from glutamine into non-essential amino acids for cell growth, whereas this nitrogen would otherwise be disposed of by GLUD activity 32 . This further suggests that which pathway from glutamate to α-ketoglutarate is used is highly dependent on the metabolic, biosynthetic and stress reduction needs of the cell.
Oncogenes and glutamine metabolism
Glutamine metabolism is upregulated by many oncogenic insults and mutations (TABLE 1) . This section highlights and expands on some of these. The MYC oncogene has perhaps been most associated with upregulated glutamine metabolism. MYC is the third most commonly amplified gene in human cancer 150 , and the discovery that MYC-transformed cells become dependent on exogenous glutamine helped to drive a resurgence of the interest in glutamine metabolism 6, 31 . MYC was found to upregulate glutamine transporters and induce the expression of GLS at the mRNA and protein levels 48, 145 , and to drive a glutamine-fuelled TCA cycle and glutathione production in hypoxia 151 . Glutamine in MYCdriven cells can be used for de novo proline synthesis 82 or production of the oncometabolite 2-hydroxyglutarate in breast cancer 152 , although the latter finding has not been independently corroborated. Infection by adeno virus or Kaposi's sarcoma-associated herpesvirus (KSHV) increases both MYC expression and glutamine metabolism 153, 154 , and in the case of KSHV this may be part of early tumorigenesis that eventually leads to Kaposi's sarcoma. MYC can also mediate the reprogramming of glutamine metabolism downstream of the activation of other oncogenic pathways, including mTOR 155 , and crosstalk with HER2 (also known as ERBB2) and the oestrogen receptor in breast cancer 156 . All these findings support the notion that glutamino lysis is a major component of MYC-driven oncogenesis in most settings.
Oncogenic KRAS-driven transformation induces dependence on glutamine metabolism 108, 119, 157 . However, different KRAS mutations can have different effects; for instance, lung cancer cells harbouring a KRAS-G12V mutation were much less glutamine-dependent than those harbouring a G12C or G12D mutation, although the reasons for this were not clear 158 . In addition to inducing dependence on glutamine-driven nucleotide metabolism 119 , mutant KRAS can increase dependence on aminotransferases through downregulation of GLUD and drive increased production of NADPH to regenerate reduced glutathione and control ROS levels 34 (FIG. 5) .
Poor vascularization and hypoxia induce the stabilization of HIF1α or HIF2α (REF. 159 ), which directs glutamine towards biosynthetic fates that do not require oxygen. HIFα stabilization orchestrates a gene expression programme that promotes the conversion of glucose to lactate, driving it away from the TCA cycle 159, 160 . Decreased glucose entry into the TCA cycle can be compensated for by glutamine-fuelled production of the TCA cycle intermediate α-ketoglutarate 151 . However, this α-ke toglutarate is largely channelled through reductive carboxylation in certain cell types to produce citrate, acetyl-CoA and lipids [89] [90] [91] . By contrast, glutamine is metabolized in human B cell lymphoma model cells cultured in hypoxia largely through forward TCA cycling, with only a minor amount undergoing reductive carboxylation 151 . HIFα stabilization can occur independently of hypoxia in tumours owing to mutations in factors involved in the degradation of HIFα subunits (such as von Hippel-Lindau tumour suppressor (VHL)) 159 or through increased translation through mTOR 161 , and glutamine itself can also increase HIFα stabilization [162] [163] [164] . We suspect that as more genes and tissues are studied, glutamine metabolism will be found to be reprogrammed through modulation of the pathways described above (TABLE 1) and through novel direct mechanisms.
Glutamine metabolism in the clinic
Imaging. Reprogrammed cancer metabolism can be used to image tumours. Glucose-based [ 165 has been in use for more than three decades to image and stage tumours via their avid uptake of glucose. However, some tissues, particularly the brain, also take up large amounts of glucose, making FDG-PET ineffective in imaging brain tumours 165 . | Two roads to α-ketoglutarate. Glutamate can be converted by one of two different pathways into α-ketoglutarate (α-KG), and the choice of which pathway is used is influenced by oncogene input and cell proliferation and metabolic state. GLS, kidney-type glutaminase; GLS2, liver-type glutaminase; GLUD, glutamate dehydrogenase; ISR, integrated stress response; ROS, reactive oxygen species.
Synthetic lethality
An effect in which two inhibitors or losses of function that, individually, do not produce death in cancer cells, if combined, synergistically induce death. Given that cancers may alter their metabolism in response to traditional chemotherapy and targeted agents, metabolic inhibitors such as inhibitors of glutamine metabolism are particularly attractive targets in synthetic lethality studies.
was developed as a potential tumour imaging tracer and validated in animal models 166, 167 , and 18 F-FGln PET has since been evaluated clinically and shown promise in the diagnosis of glioma 168 . Importantly, in glioma, 18 F-FGln accumulation does not necessarily suggest increased glutamine catabolism, as mouse orthotopic models of glioma and human patient samples show high rates of glutamine accumulation but comparatively low rates of glutamine metabolism [169] [170] [171] . Nonetheless,
18
F-FGln is a promising new tool in the diagnosis of cancers refractory to the use of FDG, such as glioma, and it will be of interest to determine whether high 18 F-FGln uptake in other tumour types is predictive of glutamine dependence and therapeutic response to inhibition of glutamine metabolism.
Therapy. The dependence of cancer cells on glutamine metabolism has made it an attractive anticancer therapeutic target. As detailed in TABLE 2, many classes of compound that target glutamine metabolism, from initial transport in the cell to conversion to α-ketoglutarate, have been examined. Although most of these are still in the preclinical 'tool compound' stage or have been limited by toxicity, allosteric inhibitors of GLS have shown promise in preclinical models of cancer, and one highly potent compound in this class, CB-839, has moved on to clinical trials. A preclinical tool compound inhibitor of GLS is bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES) 172 , which has been shown to block the growth of cancer cells in vitro and of xenografts in vivo, and to slow tumour growth and prolong survival in genetically engineered mouse models of cancer 151, 173 . CB-839 has shown efficacy against triplenegative breast cancer and haematological malignancies in preclinical studies 53, 54 , and is currently the subject of several clinical trials.
The transition of glutaminase inhibition to the clinic will be aided by understanding potential inherent or acquired resistance mechanisms. Cancers that depend on GLS2 (REFS 61,64), which is not sensitive to BPTES or CB-839, would be unlikely to respond to such therapy 174 . The expression of pyruvate carboxylase, which can provide carbon to the TCA cycle through its conversion of pyruvate to oxaloacetate, represents a potential mechanism for glutaminase independence 120, 175 . Glutamine synthetase (GLUL) expression may also predict glutamine independence and promote BPTES resistance 171, [176] [177] [178] .
Metabolic synthetic lethality and combination therapy.
The heterogeneity, varied oncogenotypes and microenvironment of tumours pose considerable challenges to targeted therapies, but the use of combination therapy is a successful paradigm in the treatment of HIV and certain types of cancer. Particularly attractive drug combinations induce synthetic lethality, in which two drugs induce cell death in combination but not individually. Many candidate preclinical synthetic-lethal treatments target pathways or cellular functions that help cancer cells to compensate for the targeting of another pathway or cellular function. The pleiotropic role of glutamine in cellular functions, such as energy production, macromolecular synthesis, mTOR activation and ROS homeo stasis 179 , makes GLS inhibition a potentially ideal candidate for combination therapy, as detailed in TABLE 3 . A few combinations are notable because they reveal novel consequences of glutamine metabolism. Specific inhibition of the anti-apoptotic protein BCL-2 synergizes with glutaminase inhibition 53 , consistent with the described role of glutamine in controlling expression and activity of pro-apoptotic and anti-apoptotic proteins, as reviewed recently 180 . Similarly, the synergism between glutamine withdrawal and chemical 
Ferroptosis
An intracellular iron-dependent form of cell death that is distinct from apoptosis.
activation of the ISR with the retinoid derivative fenretinide 65 shows that glutamine can suppress this stress response through various mechanisms, as discussed above. Although invasive and metastatic cells have not specifically been studied for their sensitivity to glutaminolysis inhibition, it has been shown that highly invasive ovarian cancer cells have increased glutamine dependence compared with less invasive cells 181 , and metastatic prostate tumours show increased glutamate avail ability and dependence on glutamine uptake 93, 182 . Indeed, genetic inhibition of glutaminase was shown to prevent epithelial-to-mesenchymal transition, a key step in tumour cell invasiveness and eventual metastasis 183 . Thus, prevention of metastasis may be another avenue to focus on in the development of combinatorial strategies in glutamine metabolic inhibition.
The effects of metabolic inhibitors in vivo may also broadly influence immunity. There has been a recent surge of interest in manipulating the immune response to target cancer, by either the blockade of immune checkpoints or the use of engineered chimeric antigen receptor (CAR) T cells. These approaches require immune cells to function within the tumour microenvironment. Recent work has indicated that immune cells compete with cancer cells for glucose 184 , and we speculate that perhaps this may be true for glutamine as well. In fact, glutamine metabolism is increased in T cell activation and regulates the skewing of CD4 + T cells towards more inflammatory subtypes 32, 185, 186 . Although ex vivo experiments suggest that lymphocytes show signs of proper activation even in the presence of CB-839 (REF. 173 ), it remains to be seen how GLS inhibition will affect antitumour immunity in vivo. Studies in mouse lymphocytes suggest that the CB-839-insensitive GLS2 may have a key role in lymphocyte proliferation 144 , and so targeting of glutamine metabolism through the modulation of tumour-specific pathways may be required to maintain both high glutamine availability and immune response.
Glutamine usage: plastic versus patient Although the crucial role of glutamine metabolism in cancer cells in vitro is well established, it is less clear what part glutamine plays in tumours in vivo, which can face shortages of nutrients and oxygen 7 . Not surprisingly, tumours use various nutrients as carbon sources and energy besides glucose and glutamine, including lipids and acetate [187] [188] [189] , and may also use macropinocytosis to support amino acid pools 22 . However, the circumstances under which macropinocytosis becomes dominant in vivo remain to be established. As an illustrative example of the metabolic complexity of tumours, lung cancer cell lines are often glutamine dependent in vitro, but a recent study of KRAS-driven mouse lung tumours demonstrated that glucose but not glutamine was preferentially used to supply carbon to the TCA cycle, through the action of pyruvate carboxylase 190 . Furthermore, two recent metabolomics and metabolic flux studies of primary human lung cancer showed little change in glutamine entry into the TCA cycle, and instead suggested that human lung cancer can synthesize glutamine from the TCA cycle 120, 191 . Human and mouse gliomas exhibit high rates of glucose catabolism and accumulate but do not avidly metabolize glutamine 168 , and do not depend on circulating glutamine to maintain cancer growth but instead use glucose to synthesize glutamine through GLUL to support nucleotide biosynthesis [169] [170] [171] . • Azaserine
16
• Acivicin
• Off-target effect on nucleotide biosynthesis 16, 226 • Limited by toxicity 16, 227 Glutamine depletion l-Asparaginase 100,101,228-230
• Off-target toxic conversion of glutamine to glutamate 231, 232 • Limited by toxicity 100,101
• FDA-approved to treat ALL Hence, much more work is needed to further define the use of nutrients in vivo, to guide the selection of metabolic therapies in the clinic. Nevertheless, glutamine metabolism has been documented as crucial for tumorigenesis and tumour survival in specific in vivo models 151, 173, 192, 193 , which have varied metabolic profiles depending on the tumour oncogenotype. The complexities in vivo are exemplified by a study using mouse models to compare the effects of metabolic driver and tissue of origin on tumour metabolism 177 (FIG. 8) . MET-driven liver tumours expressed GLUL and so presumably made their own glutamine from glucose flux, and thus do not need to take up glutamine from the environment. Likewise, MYC-driven lung tumours upregulated both GLS and GLUL, consistent with a recent study showing that MYC indirectly induces GLUL 177, 178 . Conversely, MYC-driven liver tumours upregulated GLS and SLC1A5 and avidly consumed and catabolized glutamine 173, 177 (FIG. 8) . In fact, in this same MYC-driven liver cancer model, loss of a single copy of GLS slowed tumour growth and pharmacological inhibition of GLS prolonged survival 173 , suggesting the crucial importance of glutamine metabolism in certain cancer settings. The heterogeneity of glutamine metabolism in tumours arising in the same tissue type, demonstrated by the MYC-and METdriven liver models, is mirrored in studies of human breast cancer that show that oestrogen receptor-positive breast cancer cell lines are less glutamine dependent than triple-negative breast cancer cell lines 18, 54, 176 . This finding is further supported by a study in primary oestrogen receptor-negative human breast tumours that shows a high glutamine/glutamate ratio in the tumours, suggesting increased glutamine catabolism 194 . Altered glutamine metabolism can interact with the tumour microenvironment in surprising ways. Increased lactate, which may be present in the micro environment as a consequence of increased glycolysis by cancer cells 7 , has been shown to promote increased glutamine metabolism by a HIF2-and MYC-dependent mechanism 195 , potentially providing a way for an evolving tumour to 'reprogramme' itself towards increased glutaminolysis. Similarly, as discussed above, increased glutamino lysis causes an increase in excreted ammonia and autophagy in exposed cells 137, 138 , and indeed, a study using co-culture of breast cancer cells and fibroblasts showed that the ammonia released from breast cancer cells stimulated autophagy in the fibroblasts to release additional glutamine, which was then taken up and metabolized by the cancer cells 196 . However, ammonia can be toxic to surrounding cells, and as tumours engaging in glutaminolysis may excrete large amounts of ammonia, it is still unknown how surrounding non-transformed cells detoxify this ammonia. Finally, some tumours, particularly those of the brain and the lung 120, [169] [170] [171] 191 , may synthesize and excrete glutamine, and it is still not known how this increased glutamine in the microenvironment may affect the physiology of neighbouring 
Concluding remarks
Ninety years ago, Warburg discovered that many animal and human tumours displayed high avidity for glucose, which was largely converted to lactate through aerobic glycolysis. Warburg also suggested that cancers are caused by altered metabolism and loss of mitochondrial function. These dogmatic views have been replaced and refined over the past several decades with the emergence of oncogenic alterations of metabolism, appreciation of the importance of mitochondrial oxidation in cancer physiology and the rediscovery of the role of glutamine in tumour cell growth in addition to the pivotal role of glucose. In this Review, we provide an updated overview of glutamine metabolism in cancers and discuss the complexity of metabolic rewiring as a function of the tumour oncogenotype as well as the micro environment, which adds to the heterogeneity found in vivo. In certain types of cancer, such as those driven by MYC, tumour cells seem to depend on glutamine, and hence targeting glutamine metabolism pharmacologically may prove beneficial. Conversely, different oncogenic drivers may result in tumour cells that could bypass the need for glutamine. However, targeted inhibition of some oncogenic drivers has been reported to rewire cells to become dependent on glutamine, and hence targeted inhibitors could be synthetically lethal with inhibition of glutamine metabolism. Overall, the field of cancer metabolism has made considerable progress in understanding alternative fuel sources for cancers, including glutamine, which under specific circumstances can be exploited for therapeutic purposes. .
